At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|December 24, 2021
Dr. Curtis Pettaway’s achievements and contributions in the field of urology
Author(s)Urology Times staff
“We…had 1 of the largest African American hereditary prostate cancer projects funded through the National Cancer Institute,” says Curtis A. Pettaway, MD.
Advertisement
In this video, Curtis A. Pettaway, MD, discusses the contributions and achievements that led him to receive the Society of Urologic Oncology’s 2021 Huggins Medal. Pettaway is a professor of urology at the University of Texas MD Anderson Cancer Center in Houston.
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
How PSMA-PET shapes staging and recurrence workup in prostate cancer
3
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5